An analysis led by researchers at Fox Chase Cancer Center in collaboration with the European Organization for the Research and Treatment of Cancer found that treating cancer that has metastasized to the brain with focal, high-dose radiation yields improved early results compared with surgical removal.
Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for women who undergo immediate breast reconstruction after mastectomy.
A recent study confirmed the International Association for the Study of Lung Cancer's proposed criteria for uncertain resection margin status, R(un), in residual tumor (R) classification.
As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.
AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, said the FDA has granted accelerated approval to Calquence (acalabrutinib, previously known as ACP-196), a kinase inhibitor, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Scientists from within the industry, academia, and two U.S. national laboratories are working to streamline the process for development of cancer drugs. They are creating an open and sharable platform that integrates high-performance computing, shared biological data from public and industry sources, and emerging biotechnologies to dramatically accelerate the discovery.
Kelly McMasters was appointed as the new editor-in-chief of Annals of Surgical Oncology effective March 2018. The journal is published by the Society of Surgical Oncology.
The Focused Ultrasound Foundation said it has received a pledge of $10 million in unrestricted funds from an anonymous donor to be matched 1:1 by 2022.
NCI has awarded an $8.3 million grant to the University of Arkansas for Medical Sciences for expansion and enhancement of an archive containing freely accessible cancer medical images and data.
The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious diseases, and Man's Best Friend Therapeutics Inc., an animal health company, are entering into an exclusive license agreement for the advancement of immunotherapeutic vaccines for companion and domestic animals based on technology created at Wistar.
